Collaborative and Other Relationships (Tables)

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:



Until GAZYVA First Non-CLL FDA Approval	40.0	%
After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date	39.0	%
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date	37.5	%
After Second GAZYVA Threshold Date	35.0	%

First Non-CLL GAZYVA FDA Approval means the FDA’s first approval of GAZYVA in an indication other than CLL.

First GAZYVA Threshold Date means the earlier of (i) the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least $150.0 million or (ii) the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $150.0 million.

Second GAZYVA Threshold Date means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0 million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.

Pretax profit sharing formula

Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:



Until First GAZYVA Threshold Date	39.0	%
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date	37.5	%
After Second GAZYVA Threshold Date	35.0	%

Revenues from anti-CD20 therapeutic programs

Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.



	For the Years Ended December 31,
(In millions)	2019		2018		2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses	$	1,542.4	$	1,431.9	$	1,316.4
Other revenues from anti-CD20 therapeutic programs	748.0		548.3		242.8
Total revenues from anti-CD20 therapeutic programs	$	2,290.4	$	1,980.2	$	1,559.2

Revenues from anti-CD20 therapeutic programs are summarized as follows:



	For the Years Ended December 31,
(In millions)	2019		2018		2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses	$	1,542.4	$	1,431.9	$	1,316.4
Other revenues from anti-CD20 therapeutic programs	748.0		548.3		242.8
Total revenues from anti-CD20 therapeutic programs	$	2,290.4	$	1,980.2	$	1,559.2

Summary of activity related to BAN2401 and Elenbecestat collaboration

A summary of development and sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:



	For the Years Ended December 31,
(In millions)	2019		2018		2017
Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat	$	348.7	$	232.0	$	146.2
Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income	$	174.3	$	116.0	$	74.3

Total sales and marketing expense incurred by the collaboration	$	32.4	$	10.7	$	—
Biogen's share of BAN2401 and Elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income	$	16.2	$	5.4	$	—

Summary of activity related to Aducanumab collaboration

A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:



	For the Years Ended December 31,
(In millions)	2019		2018		2017
Total aducanumab development expense	$	179.4	$	264.8	$	268.7
Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income	$	98.7	$	234.6	$	268.7

Total aducanumab sales and marketing expense incurred by the collaboration	$	27.4	$	50.6	$	23.6
Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income	$	15.1	$	27.3	$	23.6